Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
Progression is “uncommon” in patients with relapsed/refractory large B-cell lymphoma who are in complete remission at the end of glofitamab treatment.
Researchers sought to evaluate cognitive function in patients with hematologic cancers and the feasibility conducting cognitive assessments remotely in these patients.
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.
The incidence of cutaneous T-cell lymphoma in the United States increased from 2000 to 2018, with an annual percent change of 0.61%.
Researchers sought to determine the incidence and possible risk factors of acute kidney injury in patients undergoing a chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
Authors suggest increase may be associated with increasing prevalence of textured implants during the same period.
Researchers sought to determine whether the combination pola-R-CHP would be cost-effective for treating patients with previously untreated DLBCL.
